Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis

BACKGROUND: Lenvatinib is approved for patients with advanced hepatocellular carcinoma (HCC) due to its non-inferiority to sorafenib of overall survival (OR) in clinical trials. This study was to compare the effectiveness and safety of lenvatinib and sorafenib in the real world. METHODS: We retrospe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Yuan-Hung, Lu, Sheng-Nan, Chen, Yen-Yang, Kee, Kwong-Ming, Yen, Yi-Hao, Hung, Chao-Hung, Hu, Tsung-Hui, Chen, Chien-Hung, Wang, Jing-Houng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573180/
https://www.ncbi.nlm.nih.gov/pubmed/34760699
http://dx.doi.org/10.3389/fonc.2021.737767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573180/
https://www.ncbi.nlm.nih.gov/pubmed/34760699
http://dx.doi.org/10.3389/fonc.2021.737767

Ejemplares similares